Summary: Treatment-Naive Genotype 1a Without Cirrhosis
Recommended regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 1a Patients Without Cirrhosis
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs for elbasvira
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b
|
8 weeks
|
I, A
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
|
12 weeks
|
I, A
|
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL
|
8 weeks
|
I, B
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
|
12 weeks
|
I, A
|
a Includes genotype 1a resistance-associated substitutions (RASs) at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance. If 1 or more RASs are present, another recommended regimen should be used.
b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
|
